BioMarin Pharmaceutical Inc. is moving forward with its previously announced plan to acquire Amicus Therapeutics, Inc. In an update, Amicus disclosed that as of December 31, 2025, it had approximately $294 million in cash, cash equivalents, and marketable securities. For the year ended December 31, 2025, Amicus reported estimated total net product revenues of about $634 million, with $522 million generated from Galafold® and $112 million from Pombiliti® + Opfolda®. These preliminary financial results were shared as part of BioMarin's preparations for a proposed private placement of senior notes to help finance the acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-002299), on January 26, 2026, and is solely responsible for the information contained therein.